Eyeworld Daily News

2016 ASCRS New Orleans Daily Tuesday

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: https://daily.eyeworld.org/i/677598

Contents of this Issue

Navigation

Page 9 of 64

IMPORTANT SAFETY INFORMATION OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% must be added to irrigation solution prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma. The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. Use of OMIDRIA in children has not been established. INDICATIONS AND USAGE OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. Reference: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2015. Please see the Full Prescribing Information at www.omidria.com/ prescribinginformation. Visit www.omidria.com • Preempt miosis and inhibit postoperative pain 1 • Block the surgically induced inflammatory cascade with the first and only NSAID FDA-approved for intracameral use 1 • Eliminate the risks and liabilities of compounded products by using FDA-approved OMIDRIA • Avoid reimbursement difficulties by using broadly covered OMIDRIA and the OMIDRIAssure™ services THE POWER OF PREEMPTION OMIDRIA ® is the first and only FDA-approved drug that provides continuous intracameral delivery of NSAID and mydriatic/anti-miotic therapy during cataract surgery 1 CHOOSE OMIDRIA FOR YOUR NEXT CATARACT SURGERY PATIENT LEARN MORE AT BOOTH #1117 OMEROS®, the OMEROS® logo, OMIDRIA®, and the OMIDRIA logo® are registered trademarks and OMIDRIAssure™ is a trademark of Omeros Corporation. © Omeros Corporation 2016, all rights reserved. 2016-095

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld Daily News - 2016 ASCRS New Orleans Daily Tuesday